Evaluation of Different Perimetric Grids to Detect Central Visual Field Defect in Glaucoma Patients with Reduce Ganglion Cell Layer Thickness Measured by Spectral Domain OCT.
1 other identifier
observational
16
1 country
2
Brief Summary
The aim of the study is to evaluate the agreement between three different grids in detecting central visual field defect in early glaucoma patients with reduced ganglion cell layer thickness.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started May 2021
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 4, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 4, 2022
CompletedFirst Submitted
Initial submission to the registry
January 18, 2024
CompletedFirst Posted
Study publicly available on registry
January 29, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 4, 2025
CompletedFebruary 27, 2025
February 1, 2025
1 year
January 18, 2024
February 25, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
the agreement between 10-2 HFA and 24-2c HFA in detecting central visual field defect
central visual field is defined by the presence of a cluster of three test locations with significantly reduced sensitivity in a hemifield fo the pattern deviation plot.
12 month
Secondary Outcomes (1)
the agreement between 24-2c HFA and G1 Octopus in detecting central visual field defect
12 month
Eligibility Criteria
glaucoma patients referring to glaucoma clinic of IRCCS-Fondazione GB Bietti and University of Rome Tor Vergata.
You may qualify if:
- glaucoma patients with glaucomatous optic nerve head defect and reduced ganglion cell layer thickness
You may not qualify if:
- age\<18 years
- unable to read, understand and sign the written informed consent
- unable to perform visual field test
- advanced glaucoma with C/D\>0.7
- other causes of optic neuropathies
- retinal or macular diseases
- lens or corneal opacities
- spherical refractive defect \>± 6D
- cylindric refractive defect \>± 3D
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
IRCCS-Fondazione GB Bietti
Rome, Italy
University of Rome Tor Vergata
Rome, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 18, 2024
First Posted
January 29, 2024
Study Start
May 4, 2021
Primary Completion
May 4, 2022
Study Completion
May 4, 2025
Last Updated
February 27, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share